Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer
ConclusionsThere is a considerable lack of evidence regarding the role of adjuvant radiotherapy and its individualization based on treatment response after NACT. Results of prospective randomized trials such as NSABP B‑51/RTOG 1304 and Alliance A11202 are eagerly awaited.
CONCLUSIONSFor patients with Luminal/HER2 negative breast cancer, the combination of the imaging features of the tumor and the mammary gland, obtained with 18F-FDG PET-CT at baseline and after the first cycle of NAC, may allow the physician to evaluate the probability of BCS.
CONCLUSION: This is one of the largest comprehensive data from a single center in India. Majority of our patients are younger in age and have advanced disease. TNBC and HER2/neu positive breast cancer are more common in our population.
Publication date: Available online 17 January 2019Source: European Journal of Surgical OncologyAuthor(s): Elbert J. Mets, Fouad K. Chouairi, Kyle S. Gabrick, Tomer Avraham, Michael AlperovichAbstractBackgroundRacial disparities among patients who receive breast mastectomy and reconstruction have not been well characterized.MethodsRecords of patients undergoing breast extirpative and reconstructive surgery at a high-volume university-affiliated hospital over 5 consecutive years were reviewed. Patient demographics, breast cancer profiles, reconstructive modality, and outcomes were compared by race.ResultsA total of 1045 pati...
A 59-year-old woman with a history of right-sided breast cancer presents with new onset of a right lower neck mass and numbness/paresthesia over her anterior/medial deltoid.1 Three years earlier, she received a diagnosis of stage IIIA disease (cT3N1), ER/PR+ and Her-2 nonreactive. She received neoadjuvant chemotherapy followed by modified radical mastectomy and adjuvant chemotherapy. However, she did not receive postmastectomy radiation or proper hormone therapy because of their cost.
Publication date: Available online 29 December 2018Source: European Journal of Surgical OncologyAuthor(s): E. Heeg, K. Schreuder, P.E.R. Spronk, J.C. Oosterwijk, P.J. Marang-van de Mheen, S. Siesling, M.T.F.D. Vrancken Peeters, NABON Breast Cancer AuditAbstractPurposePatients may transfer of hospital for clinical reasons but this may delay time to treatment. The purpose of this study is to provide insight in the extent of hospital transfer in breast cancer care; which type of patients transfer and what is the impact on time to treatment.MethodsWe included 41,413 breast cancer patients registered in the Netherlands Cancer R...
CONCLUSION: BCS after NACT is feasible and safe in terms of LRR, DFS and OS, if patients are properly studied and selected. Indication to BCS after NACT needs of a multidisciplinary assessment considering clinical staging, biological characteristics, the radiological response pattern and the expected concordance between imaging and histology. KEY WORDS: Breast Cancer, Breast-conserving surgery, Neoadjuvant chemotherapy. PMID: 30569900 [PubMed - in process]
CONCLUSION: Although there was a significantly higher number of patients achieving pCR among HR-/HER2+ subtype compared to other BC subtypes, this did not translate into improvement in long-term disease outcome of these patients. PMID: 30570847 [PubMed - in process]
This study aimed to evaluate the effects of NC on depth of total intravenous anesthesia. This prospective observational study enrolled 60 patients undergoing elective unilateral modified radical mastectomy during total intravenous anesthesia with propofol and remifentanil (January–June 2015; Liaocheng People's Hospital, China): the NC group (n = 30) received NC, while the control group (n = 30) did not. Propofol and remifentanil dosages were adjusted according to indexes of consciousness (IoC1: sedation; IoC2: analgesia) to control fluctuations of blood pressure and heart rate within 20% of baseline values. ...
ConclusionsAfter NAC, most patients received irradiation of the breast/chest wall and axillary and supraclavicular nodes. In this setting, PORT to breast/chest wall with or without regional nodal irradiation was safe and effective, with acceptable disease-free and overall survival rates reported in this high-risk population.
Conclusions: This study is consistent with previous research showing that breast-conserving surgery after neoadjuvant chemotherapy does not reduce breast cancer–specific survival. In fact, patients undergoing breast-conservation after neoadjuvant therapy appeared to have better survival than patients undergoing mastectomy without radiation.